Jesus Martin
Sevilla, AN, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma.
Journal: Blood cancer discovery
Published: October 01, 2024
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.
Journal: Annals of hematology
Published: July 24, 2024
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 06, 2022
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.
Journal: Blood advances
Published: December 03, 2021
Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Journal: Blood
Published: May 04, 2021
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.
Journal: Blood cancer journal
Published: January 18, 2021
Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study.
Journal: British journal of haematology
Published: December 04, 2019
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 27, 2019
Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.
Journal: Leukemia
Published: March 09, 2019
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation.
Journal: Bone marrow transplantation
Published: January 09, 2019
Last Updated: 09/26/2026